Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...

Lilly's Ebglyss delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis: Indianapolis Monday, March 30, 2026, 12:00 Hrs [IST] ...

墙壁“冒汗”、袜子不干、空气能拧出水来——广东人的“回南天”来了！有人盼着雨过天晴，可特应性皮炎（Atopic dermatitis，AD）患者却要开始“渡劫”：在回南天这种高温、高湿、霉菌滋生的“三重打击”下，本就脆弱的皮肤屏障更容易崩溃。皮肤像火山喷发一样红肿，甚至流黄水、结厚痂，瘙痒钻心彻夜难眠，“皮肤里像有虫子在爬，抓破了才舒服，可越抓越痒”。 一、为什么回南天会让病情雪上加霜？ 1、皮肤 ...

Kymera Therapeutics recently reported positive BroADen Phase 1b data for KT-621, an oral STAT6 degrader, showing deep target engagement and clinically meaningful improvements in adults with ...

Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.

长久以来，我们对“身心交汇”的理解往往停留在抽象的经验层面。当我们面临巨大的心理压力时，皮肤往往会给出最直接的抗议——瘙痒、红斑、甚至难以愈合的皮疹。对于特应性皮炎 (Atopic dermatitis, ...

Itch relief - defined as a score of ≥4 on the Peak Pruritus Numerical Rating Scale (PP-NRS) - was observed as early as Week 1, with 72% of children aged 2 to 6 and 59% of children aged 7 to 11 ...

New research links atopic dermatitis to S1P signalling pathways driving inflammation. Learn how this could shape future ...

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today presented positive long-term ...

Apogee Therapeutics shares rally as Phase 2 APEX data show durable atopic dermatitis control with 3- or 6-month dosing.

The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship ...